Advertisement
Advertisement
Advertisement
Advertisement
Heart failure Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (ventricular dysfunction), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as myocardial infarction. Total Anomalous Pulmonary Venous Return (TAPVR) (HF) refers to a complex condition resulting from the structural and/or functional inability of the heart to supply a normal cardiac output Cardiac output The volume of blood passing through the heart per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with stroke volume (volume per beat). Cardiac Mechanics to meet metabolic needs. In HF, impaired ventricular filling Ventricular filling Cardiac Cycle or ejection of blood leads to fatigue Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Fibromyalgia, dyspnea Dyspnea Dyspnea is the subjective sensation of breathing discomfort. Dyspnea is a normal manifestation of heavy physical or psychological exertion, but also may be caused by underlying conditions (both pulmonary and extrapulmonary). Dyspnea, and fluid retention or edema Edema Edema is a condition in which excess serous fluid accumulates in the body cavity or interstitial space of connective tissues. Edema is a symptom observed in several medical conditions. It can be categorized into 2 types, namely, peripheral (in the extremities) and internal (in an organ or body cavity). Edema. Echocardiography Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Tricuspid Valve Atresia (TVA) can confirm the diagnosis, providing information about the ejection fraction Ejection fraction Cardiac Cycle ( EF EF Cardiac Cycle) and the adequacy of ventricular filling Ventricular filling Cardiac Cycle and relaxation. Treatment is directed at the removal of excess fluid and decreasing oxygen demand of the heart. Prognosis Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Non-Hodgkin Lymphomas depends on the underlying cause, compliance Compliance Distensibility measure of a chamber such as the lungs (lung compliance) or bladder. Compliance is expressed as a change in volume per unit change in pressure. Veins: Histology with medical therapy, and presence of comorbidities Comorbidities The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival. St. Louis Encephalitis Virus.
Last updated: Nov 21, 2024
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Underlying conditions include:
Risk factors include:
By duration:
By ejection fraction Ejection fraction Cardiac Cycle ( EF EF Cardiac Cycle):
By the area affected:
Left HF | Right HF | |
---|---|---|
Symptoms |
|
|
Signs and examination findings |
|
|
This system classifies cases based on the degree of effort to evoke breathlessness but does not correlate with the degree of cardiac structure abnormalities.
The diagnostic approach may vary based on practice location. The following information was derived from US-based practices. Additional recommendations in other regions are available for review (UK, Europe).
Laboratory tests evaluate risk factors, preexisting conditions, and reversible causes of heart dysfunction.
Cardiac markers:[2,6,7,13,15,20]
Additional studies:[2,6,13,17]
Electrocardiography Electrocardiography Recording of the moment-to-moment electromotive forces of the heart as projected onto various sites on the body’s surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a cathode ray tube display. Electrocardiogram (ECG) ( ECG ECG An electrocardiogram (ECG) is a graphic representation of the electrical activity of the heart plotted against time. Adhesive electrodes are affixed to the skin surface allowing measurement of cardiac impulses from many angles. The ECG provides 3-dimensional information about the conduction system of the heart, the myocardium, and other cardiac structures. Electrocardiogram (ECG)):[2,6,13,20,27]
Chest X-ray X-ray Penetrating electromagnetic radiation emitted when the inner orbital electrons of an atom are excited and release radiant energy. X-ray wavelengths range from 1 pm to 10 nm. Hard x-rays are the higher energy, shorter wavelength x-rays. Soft x-rays or grenz rays are less energetic and longer in wavelength. The short wavelength end of the x-ray spectrum overlaps the gamma rays wavelength range. The distinction between gamma rays and x-rays is based on their radiation source. Pulmonary Function Tests ( CXR CXR X-ray visualization of the chest and organs of the thoracic cavity. It is not restricted to visualization of the lungs. Pulmonary Function Tests):[2,6,13,27]
A good mnemonic to remember these findings on CXR CXR X-ray visualization of the chest and organs of the thoracic cavity. It is not restricted to visualization of the lungs. Pulmonary Function Tests is ABCDE:
Transthoracic echocardiography Transthoracic Echocardiography Imaging of the Heart and Great Vessels ( TTE TTE Imaging of the Heart and Great Vessels) with Doppler Doppler Ultrasonography applying the doppler effect, with frequency-shifted ultrasound reflections produced by moving targets (usually red blood cells) in the bloodstream along the ultrasound axis in direct proportion to the velocity of movement of the targets, to determine both direction and velocity of blood flow. Ultrasound (Sonography) imaging:[2,6,13,15,20,22]
Cardiac magnetic resonance Cardiac magnetic resonance Aortic Regurgitation imaging ( CMR CMR Imaging of the Heart and Great Vessels):[1,2,6,13,25]
Multigated acquisition scan Multigated acquisition scan Heart Failure ( radionuclide ventriculography Radionuclide ventriculography Heart Failure):[2,25]
Cardiopulmonary exercise testing (CPET):[2,13,25]
Test | Findings |
---|---|
BNP BNP A peptide that is secreted by the brain and the heart atria, stored mainly in cardiac ventricular myocardium. It can cause natriuresis; diuresis; vasodilation; and inhibits secretion of renin and aldosterone. It improves heart function. It contains 32 amino acids. Renal Sodium and Water Regulation/pro-BNP |
|
Chest X-ray X-ray Penetrating electromagnetic radiation emitted when the inner orbital electrons of an atom are excited and release radiant energy. X-ray wavelengths range from 1 pm to 10 nm. Hard x-rays are the higher energy, shorter wavelength x-rays. Soft x-rays or grenz rays are less energetic and longer in wavelength. The short wavelength end of the x-ray spectrum overlaps the gamma rays wavelength range. The distinction between gamma rays and x-rays is based on their radiation source. Pulmonary Function Tests |
|
ECG ECG An electrocardiogram (ECG) is a graphic representation of the electrical activity of the heart plotted against time. Adhesive electrodes are affixed to the skin surface allowing measurement of cardiac impulses from many angles. The ECG provides 3-dimensional information about the conduction system of the heart, the myocardium, and other cardiac structures. Electrocardiogram (ECG) |
|
Echocardiography Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Tricuspid Valve Atresia (TVA) |
|
With clinical evaluation and initial tests confirming HF, additional tests to determine the etiology and risk stratification by classifying the stage of HF follow.
In general, HF management recommendations follow similar principles, but details of management may vary based on practice location. The following information was derived from US, European, and UK guidelines and literature.
Acute decompensated HF causes respiratory distress, generally due to accumulation of fluid in the lungs Lungs Lungs are the main organs of the respiratory system. Lungs are paired viscera located in the thoracic cavity and are composed of spongy tissue. The primary function of the lungs is to oxygenate blood and eliminate CO2. Lungs: Anatomy ( pulmonary edema Pulmonary edema Pulmonary edema is a condition caused by excess fluid within the lung parenchyma and alveoli as a consequence of a disease process. Based on etiology, pulmonary edema is classified as cardiogenic or noncardiogenic. Patients may present with progressive dyspnea, orthopnea, cough, or respiratory failure. Pulmonary Edema).
First steps:[2,13,16,36]
IV diuretic therapy:[2,6,13,16,36]
For severe hypertension Severe hypertension A confirmed blood pressure ≥ 180 mm Hg systolic and/or ≥ 120 mm Hg diastolic. Uncontrolled Hypertension, administer vasodilator therapy:[2,13,16,36]
For hypotension Hypotension Hypotension is defined as low blood pressure, specifically < 90/60 mm Hg, and is most commonly a physiologic response. Hypotension may be mild, serious, or life threatening, depending on the cause. Hypotension/ cardiogenic shock Cardiogenic shock Shock resulting from diminution of cardiac output in heart disease. Types of Shock:[2,6,13,16,35,36]
Address the precipitating factors, commonly:[2,13]
Class | Medication | Initial dose (IV) |
---|---|---|
Diuretics Diuretics Agents that promote the excretion of urine through their effects on kidney function. Heart Failure and Angina Medication | Furosemide Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. Loop Diuretics |
|
Bumetanide Bumetanide A sulfamyl diuretic. Loop Diuretics |
|
|
Torsemide Torsemide A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor. It is used for the treatment of edema associated with congestive heart failure; chronic renal insufficiency; and liver diseases. It is also used for the management of hypertension. Loop Diuretics |
|
|
Vasodilators Vasodilators Drugs used to cause dilation of the blood vessels. Thromboangiitis Obliterans (Buerger’s Disease) | Nitroglycerin Nitroglycerin A volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. It is also sometimes used for tocolysis and explosives. Nitrates |
|
Nitroprusside Nitroprusside A powerful vasodilator used in emergencies to lower blood pressure or to improve cardiac function. It is also an indicator for free sulfhydryl groups in proteins. Nitrates |
|
|
Inotropes Inotropes Hypoplastic Left Heart Syndrome (HLHS) | Dobutamine Dobutamine A catecholamine derivative with specificity for beta-1 adrenergic receptors. Sympathomimetic Drugs |
|
Milrinone Milrinone A positive inotropic cardiotonic agent with vasodilator properties. It inhibits camp phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone. Phosphodiesterase Inhibitors |
|
|
Dopamine Dopamine One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. Receptors and Neurotransmitters of the CNS |
|
|
Vasopressors Vasopressors Sepsis in Children | ||
Norepinephrine Norepinephrine Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the locus ceruleus. Receptors and Neurotransmitters of the CNS |
|
|
Vasopressin |
|
Monitoring:[2]
Additional measures:[2,15]
Discharge:[2,10,13,15,20]
Patients Patients Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures. Clinician–Patient Relationship should be referred to a cardiologist or HF program in the following situations:
To recall the management of acute heart failure Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (ventricular dysfunction), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as myocardial infarction. Total Anomalous Pulmonary Venous Return (TAPVR) or exacerbation of HF, remember LMNOP:
Lifestyle modifications decrease morbidity Morbidity The proportion of patients with a particular disease during a given year per given unit of population. Measures of Health Status and mortality Mortality All deaths reported in a given population. Measures of Health Status in heart failure Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (ventricular dysfunction), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as myocardial infarction. Total Anomalous Pulmonary Venous Return (TAPVR).
Overview:[2,13,17,20,44]
Drug classes in detail:
Therapy | Class | Medications* | Initial dose | Target dose |
---|---|---|---|---|
Guidance-directed medical therapy | ARNi ARNi Renin-Angiotensin-Aldosterone System Inhibitors | Sacubitril– valsartan Valsartan A tetrazole derivative and angiotensin II type 1 receptor blocker that is used to treat hypertension. Hypertension Drugs | 24 mg/26 mg to 49 mg/51 mg twice daily | 97 mg/103 mg twice daily |
ACEi ACEi A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. Renin-Angiotensin-Aldosterone System Inhibitors (not all are included) | Lisinopril Lisinopril One of the angiotensin-converting enzyme inhibitors (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. Renin-Angiotensin-Aldosterone System Inhibitors | 2.5‒5 mg daily | 20–40 mg daily | |
Ramipril Ramipril A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. Hypertension Drugs | 1.25‒2.5 mg daily | 10 mg daily | ||
Enalapril Enalapril An angiotensin-converting enzyme inhibitor that is used to treat hypertension and heart failure. Hypertension Drugs | 2.5 mg daily | 10–20 mg daily | ||
ARB | Losartan Losartan An antagonist of angiotensin type 1 receptor with antihypertensive activity due to the reduced pressor effect of angiotensin II. Hypertension Drugs | 25‒50 mg daily | 50–150 mg daily | |
Valsartan Valsartan A tetrazole derivative and angiotensin II type 1 receptor blocker that is used to treat hypertension. Hypertension Drugs | 20‒40 mg twice daily | 160 mg twice daily | ||
Candesartan | 4‒8 mg daily | 32 mg daily | ||
MRA |
Spironolactone Spironolactone A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. Potassium-sparing Diuretics | 12.5‒25 mg daily | 25–50 mg daily | |
Eplerenone Eplerenone A spironolactone derivative and selective aldosterone receptor antagonist that is used in the management of hypertension and congestive heart failure, post-myocardial infarction. Potassium-sparing Diuretics | 25 mg daily | 50 mg daily | ||
β-Blockers | Metoprolol Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat angina pectoris; hypertension; and cardiac arrhythmias. Antiadrenergic Drugs XL | 12.5‒25 mg daily | 200 mg daily | |
Carvedilol Carvedilol A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for alpha 1 adrenergic receptors and, at higher doses, may function as a blocker of calcium channels; it also has antioxidant properties. Carvedilol is used in the treatment of hypertension; angina pectoris; and heart failure. It can also reduce the risk of death following myocardial infarction. Class 2 Antiarrhythmic Drugs (Beta Blockers) | 3.125 mg twice daily | 25–50 mg twice daily | ||
Bisoprolol Bisoprolol A cardioselective beta-1 adrenergic blocker. It is effective in the management of hypertension and angina pectoris. Class 2 Antiarrhythmic Drugs (Beta Blockers) | 1.25 mg daily | 10 mg daily | ||
SGLT2i | Dapagliflozin Dapagliflozin Non-insulinotropic Diabetes Drugs Empagliflozin Empagliflozin Non-insulinotropic Diabetes Drugs | 10 mg daily | 10 mg daily | |
Other therapies | Loop diuretics Diuretics Agents that promote the excretion of urine through their effects on kidney function. Heart Failure and Angina Medication | Furosemide Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. Loop Diuretics | 20‒40 mg 1–2 times daily | 600 mg total daily |
Bumetanide Bumetanide A sulfamyl diuretic. Loop Diuretics | 0.5‒1 mg 1–2 times daily | 10 mg total daily | ||
Torsemide Torsemide A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor. It is used for the treatment of edema associated with congestive heart failure; chronic renal insufficiency; and liver diseases. It is also used for the management of hypertension. Loop Diuretics | 10–20 mg daily | 200 mg total daily | ||
Thiazides | Chlorothiazide Chlorothiazide A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. Hypertension Drugs | 250‒500 mg 1–2 times daily | 1000 mg total daily | |
Chlorthalidone Chlorthalidone A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. Thiazide Diuretics | 12.5‒25 mg daily | 100 mg total daily | ||
Hydrochlorothiazide Hydrochlorothiazide A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. Thiazide Diuretics | 25 mg 1–2 times daily | 200 mg total daily | ||
Indapamide Indapamide A benzamide-sulfonamide-indole derived diuretic that functions by inhibiting sodium chloride symporters. Hypertension Drugs | 2.5 mg daily | 5 mg total daily | ||
Metolazone Metolazone A quinazoline-sulfonamide derived diuretic that functions by inhibiting sodium chloride symporters. Hypertension Drugs | 2.5 mg daily | 20 mg total daily | ||
Miscellaneous | ISDN + hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication Fixed-dose combination | 20 mg ISDN and 37.5 mg hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication 3 times daily | 40 mg ISDN and 75 mg hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication 3 times daily | |
ISDN and hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication | 20–30 mg ISDN and 25–50 mg hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication 3–4 times daily | 120 mg ISDN and 300 mg hydralazine Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Heart Failure and Angina Medication total per day | ||
Ivabradine Ivabradine A benzazepine derivative and selective hyperpolarization-activated cyclic nucleotide-gated channels inhibitor that lowers the heart rate. It is used in the treatment of chronic stable angina in patients unable to take beta-adrenergic blockers, and in the treatment of heart failure. Heart Failure and Angina Medication | 5 mg twice daily | 7.5 mg twice daily | ||
Digoxin Digoxin A cardiotonic glycoside obtained mainly from digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. Cardiac Glycosides | 0.125‒0.25 mg daily | Individualized (serum level 0.5 to < 0.9 ng/mL) | ||
Vericiguat | 2.5 mg daily | 10 mg daily |
The following advanced therapies should be considered in consultation with a cardiologist.
Classification | Stage A | Stage B | Stage C | Stage D |
---|---|---|---|---|
At risk for HF | Structural heart disease, no symptoms | Structural heart disease, with symptoms | Advanced HF | |
N/A | NYHA class I | NYHA class I–IV | NYHA IV | |
General measures |
|
|||
Initial drug therapy | As indicated by other risk factors |
|
|
|
Secondary drug therapy (add-on) | N/A | N/A | In class II-IV, add:
|
|
Aside from cardiovascular complications such as arrhythmias and valvular dysfunction, long-term complications may include:
The following conditions are risk factors and/or causes of heart failure Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (ventricular dysfunction), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as myocardial infarction. Total Anomalous Pulmonary Venous Return (TAPVR):
References